15 Dec 2020 and Investor Relations Manager at Sobi, Swedish Orphan Biovitrum AB (publ). Linda assumes the responsibility for Investor Relations.

Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.Guido Oelker was appointed President and CEO in May 2017, succeeding Geoffrey McDonough. Oelkers had previously been CEO of BSN medical [].. In 2019 it had a revenue of SEK 14,248million and 1,335 employees.

Their most recent acquisition was Dova Pharmaceuticals on Sep 30, 2019. They acquired Dova Pharmaceuticals for $915M. Swedish Orphan Biovitrum AB: Invitation – Presentation of Sobi’s Q4/FY 2019 results The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi’s website prior to the telephone conference. She has more than 25 years of experience from different business roles and areas in life science companies like Astra, Johnson & Johnson and Swedish Orphan Biovitrum. She has experience from leading positions in marketing and sales as well as HR, most recently in a Global HR role at Sobi where she contributed to the growth of the company and development of the HR function. Swedish Orphan Biovitrum: Åsa Stenqvist Head of Communications and Investor Relations +46 8 697 21 88 Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for … 2021-02-19 Jorgen Winroth has joined Sobi to lead the company's Investor Relations activities.

30, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by Swedish Orphan Biovitrum AB: Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH. Publicerad: 2020-12-10 (Cision) Swedish Orphan Biovitrum AB: Sobi och Apellis redovisar positiva topline-resultat från fas 3-studien PEGASUS efter 48 veckors behandling med pegcetacoplan vid PNH Here we present financial data and our latest reports to help you understand how we are doing. You’ll also find links to more detailed investor information, in English and Swedish. Swedish Orphan Biovitrum General Information Description. Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology.

Produkterna fokuserar på inflammationssjukdomar och genetiska sjukdomar.

This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was

Swedish Orphan Biovitrum > Listed on the NASDAQ OMX Nordic Exchange Lindorff A Swedish based specialty pharmaceutical company with an international market presence. The com pany is focused on providing and developing orphan Public ppy pgpgp and niche specialist pharmaceuticals to patients with high medical needs. 2010-05-18 Investor Capital Swedish Orphan Biovitrum, även kända under namnet Sobi, är ett internationellt läkemedelsbolag.

Swedish orphan biovitrum investor relations

Sobi Annual Report 2019. Our Strategy. Our strategy established in 2017 remains in place, with refinements reflecting the evolution of the company. 2019 was a rewarding year in which we made major progress in every area of our strategy.

Störst inriktning återfinns inom tillhandahållandet av innovativa behandlingar och service för patienter med sällsynta sjukdomar. Produkterna fokuserar på inflammationssjukdomar och genetiska sjukdomar. För ytterligare information kontakta: Åsa Stenqvist, Informationsdirektör (tf), tel:08 697 21 88 eller Jörgen Winroth, e-post: jorgen.winroth@sobi.com. Om Swedish Orphan Biovitrum (Sobi) Sobi är ett internationellt läkemedelsföretag inriktat på att tillhandahålla innovativa behandlingar och service som förbättrar livet för patienter med sällsynta sjukdomar.

Investor Relations Global Contacts Swedish Orphan Biovitrum AB SOBI Morningstar Rating Rating as of Feb 23, 2021.
Folktandvården laholm priser

We are providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications.

Sobi offers this website, including the information Swedish Orphan Biovitrum AB (publ) (Sobi ™) (STO:SOBI) and Dova Pharmaceuticals, Inc. Paula Treutiger, Head of Communication & Investor Relations. 7 Jan 2021 and Investor Relations Manager at Sobi, Swedish Orphan Biovitrum AB. Linda Holmström assumes the responsibility for Investor Relations. Swedish Orphan Biovitrum s.r.o.*. 3.
Vad händer med urinvägarna vid åldrandet

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI Paula Treutiger, Head of Communication & Investor Relations 0733 666 599

30 Apr 2020 Investor Relations. Investor Swedish Orphan unit's therapy for low blood platelet count wins Chinese approval.

Tåg spel för barn

Swedish Orphan Biovitrum AB: Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH. Publicerad: 2020-12-10 (Cision) Swedish Orphan Biovitrum AB: Sobi och Apellis redovisar positiva topline-resultat från fas 3-studien PEGASUS efter 48 veckors behandling med pegcetacoplan vid PNH

RAPPORT PDF Media | Sobi Annual Report 2019. Our Strategy. Our strategy established in 2017 remains in place, with refinements reflecting the evolution of the company. 2019 was a rewarding year in which we made major progress in every area of our strategy. Swedish Orphan Biovitrum AB (publ) (Sobi™) has released the company's 2019 Annual and Sustainability Report. The integrated report summarises our business and strategy, financial performance and work on sustainability.